Lastly, the downregulation of pyruvate dehydrogenase kinase 1 (PDK1), a pyruvate dehydrogenase (PDH)-inhibitory enzyme, and the upregulation of pyruvate dehydrogenase phosphatase 2 (PDP2), a PDH-activating enzyme, confirm a metabolic shift toward Oxphos in the HLA-B,C-specific mAb B1.23.2-treated melanoma cells (Figure 2A). This evidence concerns the gene PDK1 and melanoma.